Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Total Liabilities for 8 consecutive years, with $155.2 million as the latest value for Q1 2026.

  • Quarterly Total Liabilities rose 15.74% to $155.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $155.2 million through Feb 2026, up 15.74% year-over-year, with the annual reading at $149.4 million for FY2025, 4.94% up from the prior year.
  • Total Liabilities for Q1 2026 was $155.2 million at Nurix Therapeutics, up from $149.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $155.2 million in Q1 2026, with the low at $74.4 million in Q3 2023.
  • Average Total Liabilities over 5 years is $129.5 million, with a median of $136.7 million recorded in 2024.
  • The sharpest move saw Total Liabilities crashed 36.32% in 2023, then skyrocketed 83.85% in 2024.
  • Over 5 years, Total Liabilities stood at $113.1 million in 2022, then soared by 37.18% to $155.1 million in 2023, then dropped by 8.22% to $142.4 million in 2024, then increased by 4.94% to $149.4 million in 2025, then increased by 3.92% to $155.2 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $155.2 million, $149.4 million, and $150.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.